Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
ConclusionNIC was unlikely to be cost-effective as a first-line treatment for patients with advanced NSCLC.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Yervoy